----item----
version: 1
id: {68ABE5BF-BA85-47B1-BEFC-F90CD87A2864}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/04/16/Pfizer gains FDA breakthrough status for Xalkori
parent: {D1C4EE2F-AEA4-438A-AF54-BB06F27BAC15}
name: Pfizer gains FDA breakthrough status for Xalkori
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: 761386ef-c489-41e4-bebf-17d0ad51d5cb

----field----
field: {0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
name: Taxonomy
key: taxonomy
content-length: 77

{3FA7743D-5DAB-49A3-B30D-DF5079ADB082}|{8B2376D2-D914-41D6-9402-D3CD38CABF23}
----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 51

Pfizer gains FDA 'breakthrough' status for Xalkori 
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 48

Pfizer gains FDA breakthrough status for Xalkori
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 2011

<p>The FDA has granted Pfizer's Xalkori (crizotinib) a breakthrough therapy designation as a potential treatment of patients with ROS1-positive non-small-cell lung cancer (NSCLC).</p><p>ROS1-positive represents a particular molecular subgroup of the disease &ndash; occurring in only about 1% of NSCLC patients.</p><p>Xalkori, a kinase inhibitor, already is sold on the US market as a treatment for patients with metastatic anaplastic lymphoma kinase-positive NSCLC &ndash; first gaining an accelerated approval in <a href="http://www.scripintelligence.com/home/Pfizer-granted-accelerated-OK-for-Xalkori-in-NSCLC-ahead-of-schedule-320488" target="_new">August 2011</a>, with the FDA giving its nod for a full approval in <a href="http://www.scripintelligence.com/policyregulation/FDA-converts-Pfizers-Xalkori-to-full-approval-348292" target="_new">November 2013</a>.</p><p>To gain the <a href="http://www.scripintelligence.com/home/FDA-upgrades-guide-for-breakthrough-status-other-expedited-programs-352076" target="_new">breakthrough therapy designation</a>, which was <a href="http://www.scripintelligence.com/home/All-too-easy-Obama-signs-US-FDA-user-fee-bill-without-fanfare-332602" target="_new">created</a> the <i>Food and Drug Administration Safety and Innovation Act</i>, a drug must be intended to treat a serious condition and have preliminary clinical evidence that indicates the medicine may demonstrate substantial improvement on at least one clinically significant endpoint over available therapies.</p><p>As of 17 April &ndash; the most recent date for which data are available &ndash; the FDA's Center for Drug Evaluation and Research had granted at least 74 of the 248 requests for the breakthrough designation it has received since July 2012, with regulators denying at least 124.</p><p>As of 31 March, the FDA's Center for Biologics Evaluation and Research had granted at least 11 of the 49 requests it has received for breakthrough status, denying at least 34.</p><p><p><p><p><p><p><p><p><p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 183

<p>The FDA has granted Pfizer's Xalkori (crizotinib) a breakthrough therapy designation as a potential treatment of patients with ROS1-positive non-small-cell lung cancer (NSCLC).</p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 48

Pfizer gains FDA breakthrough status for Xalkori
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150416T214142
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150416T214142
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150416T214142
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC028506
----field----
field: {2C985172-2B37-4CFE-AEDE-2A42EC833941}
name: Content Type
key: content type
content-length: 38

{832554E5-EC9E-4747-8623-6770D36CAF32}
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 51

Pfizer gains FDA 'breakthrough' status for Xalkori 
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{185C14A2-61E1-460C-96C2-EB0D8AB963B0}
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 13

Headline News
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

357920
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042333Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

761386ef-c489-41e4-bebf-17d0ad51d5cb
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042333Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
